ETV7 Limits the Antiviral and Antitumor Efficacy of CD8+ T Cells by Diverting their Fate Toward Exhaustion

0
53
Scientists demonstrated a decisive role for ETS variant 7 (ETV7) in driving CD8+T cell terminal exhaustion and revealed that ETV7 may be a promising target and biomarker for improving the efficacy of cancer immunotherapy.
[Nature Cancer]
Abstract